The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

340B Link

Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)

Brookfield Property Partners L.P.

Advised the Special Committee of Brookfield Property Partners L.P., one of the world’s premier commercial real estate companies, on its repurchase of up to $890 million of publicly held units, funded with an equity investment from Brookfield Asset Management and its affiliates

Cello Health plc

Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States

Equity stake in Bupa Arabia

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia

Global collaboration agreement with Genmab A/S

Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs

Cerner RevWorks

Advised Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services

Abacus Health Products, Inc.

Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.

Centrifuge and processing equipment business of Koki Holdings Co., Ltd.

Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment

Global rights (excluding North America) to ThermaCare (United Kingdom)

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

Asia and US rights to Physiogel

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd

50:50 Joint Venture (Australian Unity)

Advised Australian Unity, an Australian healthcare, financial services and retirement and living services company, on the formation of a strategic 50:50 joint venture with Keppel for investment opportunities in the Australian metropolitan office property sector

OurHealth

Advised OurHealth, a provider of onsite and near-site employer-sponsored primary care clinics, on its sale to General Atlantic and merger with Marathon Health

80 Collins Precinct

Advised Dexus in relation to its acquisition of the 80 Collins precinct from QIC Global Real Estate

T5 Data Centers Strategic Partnership

Advised T5 Data Centers, a leading national data center owner and operator, on the creation of a fully integrated platform with QuadReal Property Group to develop, acquire and operate data centers via a $1.0 billion investment from QuadReal

Starpharma Holdings Limited, patented VivaGel BV® product

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

Pfizer Inc. Consumer Health Business

Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture

Assets owned by GlaxoSmithKline plc

Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited

Aisthesis

Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities

Montserrat Day Hospital Group

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

Common shares and common share purchase warrants in Canopy Growth

Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants

Cura Imagem e Diagnóstico Ltda.

Advised Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners

Cura Imagem e Diagnóstico Ltda.

Advising Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners

Campbell Global

Advised CatchMark Timber Trust, Inc. on its purchase of 1.1 million acres of East Texas timberlands from Campbell Global

Concordia International Corp.

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture